Research field (7):
Environmental and pharmaceutical development resources
, Nutrition and health science
, Pharmaceuticals - chemistry and drug development
, Immunology
, Other
, Allergies and connective tissue disease
, Hematology and oncology
Research theme for competitive and other funds (25):
2022 - 2025 Development of radio-theranostics drugs against cancers using anti-EphA2 antibody
2021 - 2024 Establishment of a new preventive strategy based on the interaction of NK cells and prostate cancer stem cells
2019 - 2022 Practical research for biomarkers predicting tumorigenesis in polymyositis and dermatomyositis
2016 - 2019 Role of contraction-dependent myokines on the immune system
2014 - 2018 Preparation of microRNA from saliva and detection of cancer and prediction of drug sensitivity using saliva
2013 - 2016 Development of diagnostic system with high specificity and sensitivity for exosome derived from gynecologic cancer
2011 - 2014 Development of new target therapy for endometrial cancer stem cells
2010 - 2012 Research for novel diagnostic marker of gynecologic tumors and establishment of rapid and low invasive detection system by super-targeting antibody.
2005 - 2009 Selective targeted drug and gene delivery for cancer treatment
2007 - 2008 Development of new strategy for cord blood transplantation using enhancedleukemia-specific immune response with donor T cell
2007 - 2008 Research and development of low-invasive and high-sensitive detection system for novel tumor markers by super-targeting monoclonal antibody
2005 - 2006 Development of virus-specific immunocellular therapy after cord blood transplantation
2004 - 2005 Classification of mechanism of androgen independency in prostate cancer
2000 - 2004 腫瘍の特異的標的化を目指した遺伝子治療法の開発
2002 - 2003 Analysis of interaction of CD40 and CD40-ligand in autoimmune diseases and research for regulation drugs.
2001 - 2001 CD40リガンドを用いたヒト白血病に対する遺伝子治療の研究
2000 - 2001 Reseach for the mechanism of over-expression of soluble CD40-ligand and regulating drugs.
2000 - 2000 CD40リガンドを用いたヒト白血病に対する遺伝子治療の研究
1995 - 1997 Studies on the differention and activation mechanisms of T cell vi lymphocye functioning antigen (LFA).
1992 - 1994 Sudies on the differention and activation mechanisms of T cell via lymphocye functioning antigen (LFA).
自己免疫疾患に対する免疫制御
白血病に対する免疫細胞療法・遺伝子治療の開発研究
Show all
Papers (67):
岩澤 卓弥, 山内 卓, 福永 哲, 折田 創, 加藤 和則. 胃癌における免疫抑制調節因子および治療標的としてのMDSCs(A new subset of granulocytic MDSCs as immunosuppressive regulators and therapeutic targets in gastric cancer). 日本癌学会総会記事. 2022. 81回. J-2059
Kouki Okita, Kazuki Imai, Kazunori Kato, Reiko Sugiura, Yuichi Endo, Kazue Masuko, Yoshihisa Tomioka, Takashi Masuko. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs. Biochemical and Biophysical Research Communications. 2021. 576. 59-65
Eri Watanabe, Kazunori Kato, Takahisa Gono, Emiko Chiba, Chihiro Terai, Shigeru Kotake. Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity. Rheumatology (Oxford, England). 2021. 60. 1. 322-332